Drug
Palonosetron clinical trials
Also written Aloxi and RS 25259-197.
- studies test it
- 74
- open now
- 3
- in phase 3
- 17
- first study started
- 2005
Keep track of what changes. Save the Palonosetron studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
73 studies that test it; most in 2006 (11)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 11 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 3 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 29
- Phase 3
- 17
- Phase 4
- 16
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
- Nausea
- 24
Who runs them
Industry 16 · Other 58
Helsinn Healthcare SA (7) · M.D. Anderson Cancer Center (4) · Eisai Inc. (3) · University of Malaya (2) · OHSU Knight Cancer Institute (2) · Ajou University School of Medicine (2) · Duke University (2) · Yonsei University (2)
Often tested with
Tested in the same studies.
Dexamethasone (15) · Ondansetron (10) · Aprepitant (7) · Granisetron (5) · Fosrolapitant (3) · Olanzapine (3) · Netupitant (3) · Metoclopramide (2)
Studies
Open first, then newest update. How each study uses Palonosetron is read from its arms, and is right about nine times in ten.
Testing it · 74
- Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINVRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07726433Written as Fosrolapitant and Palonosetron Hydrochloride for Injection
- Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and VomitingNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07692451Written as Fosrolapitant and Palonosetron for injection
- The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINVRecruitingNot applicableXijing HospitalNCT05690802Written as Palonosetron hydrochloride capsules
- Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid TumorsActive, not recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07841210Written as Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine
- Cisplatin Disposition and Kidney InjuryActive, not recruitingPhase 3University of Colorado, DenverNCT03817970Written as Palonosetron
- A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine SurgeryCompletedPhase 4University of MalayaNCT06540885Written as Palonosetron (Group P)
- Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative CareCompletedPhase 2Gerhild BeckerNCT05315999Written as Palonosetron Hydrochloride
- Palonosetron vs Ondansetron In PONV Prophylaxis Among Idiopathic Scoliosis PatientsCompletedPhase 4University of MalayaNCT05956899Written as Palonosetron
- PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and VomitingCompletedPhase 2Helsinn Healthcare SANCT03204279Written as Palonosetron
- Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With CancerCompletedPhase 2/3M.D. Anderson Cancer CenterNCT03040726Written as Palonosetron
- Palonosetron vs Combination of Granisetron and Dexamethasone in Preventing PONV in Laparoscopic Cholecystectomy.CompletedPhase 4Universiti Kebangsaan Malaysia Medical CentreNCT06043336Written as Dexamethasone, granisetron & palonosetron
- Effect of Palonosetron, Ondansetron and Dexamethasone in the Prevention of Postoperative Nausea and VomitingStatus unknownPhase 3Selcuk UniversityNCT05439798Written as Palonosetron+Dexamethasone
- An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and VomitingCompletedPhase 3Helsinn Healthcare SANCT01363479Written as Oral palonosetron
- Evaluate Bioequivalence of Palonosetron (0.25mg/5mL)CompletedPhase 4Yung Shin Pharm. Ind. Co., Ltd.NCT04585412Written as Palonosetron
- Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell TransplantCompletedPhase 2OHSU Knight Cancer InstituteNCT03097588Written as Palonosetron Hydrochloride
- Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in FemaleCompletedNot applicableAjou University School of MedicineNCT04563260Written as Palonosetron Injection [Aloxi]
- Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)CompletedPhase 2Eisai Inc.NCT00967499Written as Palonosetron
- A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)CompletedPhase 2Eisai Inc.NCT01054456Written as palonesetron
- Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCPStatus unknownPhase 4Theodor Bilharz Research InstituteNCT04576390Written as Palonosetron 75 mcg
- A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerCompletedPhase 3Helsinn Healthcare SANCT03403712Written as fosnetupitant/ palonosetron
See all 74 studies that test Palonosetron →
Given in every arm · 14 — Palonosetron is usual care beside what is tested
- Tegileridine vs Sufentanil for Postoperative Pain Management and Gastrointestinal Recovery After Major Laparoscopic Abdominal SurgeryNot yet recruitingPhase 4Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07637968Written as Palonosetron
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HECRecruitingPhase 4Shanghai 6th People's HospitalNCT07482891Written as Fosrolapitant and Palonosetron Hydrochloride for Injection
- A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With ChemoradiationRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT04308837Written as Palonosetron
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05841849Written as Palonosetron
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic ChemotherapyCompletedPhase 3Alliance for Clinical Trials in OncologyNCT03578081Written as Palonosetron Hydrochloride
- Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT01836705Written as Panolosetron
- Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic ChemotherapyCompletedPhase 3Sun Yat-sen UniversityNCT03674294Written as Palonosetron
- Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast CancerCompletedPhase 2Instituto Brasileiro de Controle do CancerNCT04669132Written as Palonesetron
- Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For CancerCompletedPhase 3M.D. Anderson Cancer CenterNCT00553059Written as palonosetron hydrochloride
- Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and VomitingCompletedPhase 3First Affiliated Hospital of Harbin Medical UniversityNCT02484911Written as Palonosetron
- Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedPhase 1Intarcia TherapeuticsNCT02650479Written as Palonosetron
- Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and VomitingCompletedPhase 3China Medical University, ChinaNCT02203253Written as Palonosetron and Dexamethasone
- Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin ChemotherapyStatus unknownPhase 2Zhejiang UniversityNCT02445872Written as Palonosetron
- Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus PaclitaxelStatus unknownPhase 2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT02290470Written as Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
As the comparator · 12 — what is tested is compared with Palonosetron
- QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous AdministrationNot yet recruitingPhase 1Qilu Pharmaceutical (Hainan) Co., Ltd.NCT07817004Written as palonosetron hydrochloride injection
- An Relative Bioavailability Study of BH006 for Injection in Healthy SubjectsNot yet recruitingEarly Phase 1Zhuhai Beihai Biotech Co., LtdNCT06427681Written as Fosaprepitant for injection+Palonosetron hydrochloride injection
- Efficacy of Palonosetron Plus Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Gynaecological Laparoscopic SurgeryCompletedPhase 4Bangladesh Medical UniversityNCT07813897Written as Palonosetron
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for CancerCompletedPhase 3Heron TherapeuticsNCT00343460Written as Palonosetron Hydrochloride
- Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and VomitingCompletedPhase 2Xiamen LP Pharmaceutical Co., LtdNCT04592198Written as Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MECStatus unknownPhase 3Xiamen LP Pharmaceutical Co., LtdNCT05199818Written as IV Palonosetron 0.25 mg
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Palonosetron
- Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and DexamethasoneCompletedPhase 4Kangdong Sacred Heart HospitalNCT02532634Written as palonosetron, aprepitant, dexamethasone
- Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 PolymorphismCompletedPhase 4Yonsei UniversityNCT02480088Written as Palonosetron
- An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedPhase 3Helsinn Healthcare SANCT01339260Written as Palonosetron
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedPhase 3Helsinn Healthcare SANCT01376297Written as Palonosetron
- Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine SurgeryCompletedNot applicableYonsei UniversityNCT01825733Written as palonosetron
Codes
What other systems call Palonosetron · ClinicalTrials.gg INT006814
- MeSH (NLM) D000077924PalonosetronConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5D06587D6RPALONOSETRONConfirmed FDA, NLM, Wikidata
- RxNorm 70561Confirmed FDA, Wikidata
- Wikidata Q419841(3aS)-palonosetronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61874PalonosetronOne source FDA
- DrugBank DB00377One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077924 | Palonosetron | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5D06587D6R | PALONOSETRON | Confirmed FDA, NLM, Wikidata |
| RxNorm | 70561 | — | Confirmed FDA, Wikidata |
| Wikidata | Q419841 | (3aS)-palonosetron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61874 | Palonosetron | One source FDA |
| DrugBank | DB00377 | — | One source Wikidata |
Also registered as palonosetron hydrochloride (UNII 23310D4I19 · RxNorm 397405) and palonosetron, (3r)- (UNII 2UCB21ER4V).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.